Side Effects
AOD-9604 demonstrated a favorable safety profile across six clinical trials, with adverse event rates that were not significantly different from placebo. The most commonly reported effects were mild and transient.
Commonly reported:
- Mild injection-site reactions (redness, swelling, or tenderness), typically resolving within 24 to 48 hours
- Occasional mild headaches
- Transient fatigue during the initial days of use
Not observed in clinical trials:
- No elevation of IGF-1 levels
- No impairment of glucose tolerance or carbohydrate metabolism
- No insulin resistance
- No anti-AOD-9604 antibody formation
- No fluid retention or joint pain
- No serious adverse events attributed to AOD-9604
Important limitations: The longest clinical trial duration was 24 weeks, and no data exist on effects beyond six months of use. The total clinical trial population was 893 participants, which is relatively small for detecting rare adverse events. Long-term safety data, particularly for subcutaneous injection routes not studied in the original trials, remain unavailable. The clinical trials used oral dosing; subcutaneous injection protocols common in community use have not undergone formal safety evaluation.